(MRK) Merck KGaA - Overview
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE0006599905
Stock:
Total Rating 48
Risk 96
Buy Signal 0.18
| Risk 5d forecast | |
|---|---|
| Volatility | 25.4% |
| Relative Tail Risk | -6.80% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.23 |
| Alpha | -16.40 |
| Character TTM | |
|---|---|
| Beta | 0.524 |
| Beta Downside | 0.765 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.42% |
| CAGR/Max DD | -0.19 |
EPS (Earnings per Share)
Revenue
Description: MRK Merck KGaA
Merck KGaA operates as a science and technology company in Germany and internationally. It operates through Life Science, Healthcare, and Electronics segments. The Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as the industrial sector. This segment offers science and lab solutions comprising reagents, consumables, devices, instruments, software, and services for research, production, and testing; process solutions consisting of filtration devices, chromatography resins, single-use systems, process chemicals, and excipients; and life science services, such as monoclonal antibodies, high-potency active pharmaceutical ingredients, antibody-drug conjugates, and viral and gene therapy products, as well as contract development, manufacturing, and testing services. Its Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, cardiovascular, metabolism, and endocrinology disorders; and provides general medicines, injection devices, and disease monitoring software. The Electronics segment supplies materials comprising thin films, patterning and planarization formulations, specialty gases, optronics, and optical metrology equipment for the semiconductor and display industries, as well as provides delivery systems and services. It has in-licensing agreements with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 2.96b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.24 > 1.0 |
| NWC/Revenue: 19.93% < 20% (prev 16.53%; Δ 3.39% < -1%) |
| CFO/TA 0.08 > 3% & CFO 3.87b > Net Income 2.96b |
| Net Debt (9.85b) to EBITDA (6.00b): 1.64 < 3 |
| Current Ratio: 1.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (435.7m) vs 12m ago 0.18% < -2% |
| Gross Margin: 58.69% > 18% (prev 0.59%; Δ 5810 % > 0.5%) |
| Asset Turnover: 42.09% > 50% (prev 41.81%; Δ 0.28% > 0%) |
| Interest Coverage Ratio: 11.30 > 6 (EBITDA TTM 6.00b / Interest Expense TTM 359.0m) |
Altman Z'' 3.84
| A: 0.08 (Total Current Assets 12.88b - Total Current Liabilities 8.64b) / Total Assets 50.93b |
| B: 0.48 (Retained Earnings 24.20b / Total Assets 50.93b) |
| C: 0.08 (EBIT TTM 4.06b / Avg Total Assets 50.53b) |
| D: 1.15 (Book Value of Equity 25.12b / Total Liabilities 21.93b) |
| Altman-Z'' Score: 3.84 = AA |
Beneish M -2.98
| DSRI: 1.04 (Receivables 4.34b/4.11b, Revenue 21.27b/20.96b) |
| GMI: 1.00 (GM 58.69% / 58.60%) |
| AQI: 1.04 (AQ_t 0.56 / AQ_t-1 0.53) |
| SGI: 1.01 (Revenue 21.27b / 20.96b) |
| TATA: -0.02 (NI 2.96b - CFO 3.87b) / TA 50.93b) |
| Beneish M-Score: -2.98 (Cap -4..+1) = A |
What is the price of MRK shares?
As of February 27, 2026, the stock is trading at EUR 125.65 with a total of 189,775 shares traded.
Over the past week, the price has changed by -1.76%, over one month by -2.14%, over three months by +8.55% and over the past year by -6.42%.
Over the past week, the price has changed by -1.76%, over one month by -2.14%, over three months by +8.55% and over the past year by -6.42%.
Is MRK a buy, sell or hold?
Merck KGaA has no consensus analysts rating.
What are the forecasts/targets for the MRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 150.8 | 20% |
| Analysts Target Price | - | - |
MRK Fundamental Data Overview February 21, 2026
Market Cap USD = 65.92b (55.72b EUR * 1.1832 EUR.USD)
P/E Trailing = 18.8456
P/E Forward = 14.7275
P/S = 2.6194
P/B = 1.8962
P/EG = 2.697
Revenue TTM = 21.27b EUR
EBIT TTM = 4.06b EUR
EBITDA TTM = 6.00b EUR
Long Term Debt = 6.37b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 1.65b EUR (from shortTermDebt, last quarter)
Debt = 12.10b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.85b EUR (from netDebt column, last quarter)
Enterprise Value = 64.90b EUR (55.72b + Debt 12.10b - CCE 2.92b)
Interest Coverage Ratio = 11.30 (Ebit TTM 4.06b / Interest Expense TTM 359.0m)
EV/FCF = 33.56x (Enterprise Value 64.90b / FCF TTM 1.93b)
FCF Yield = 2.98% (FCF TTM 1.93b / Enterprise Value 64.90b)
FCF Margin = 9.09% (FCF TTM 1.93b / Revenue TTM 21.27b)
Net Margin = 13.90% (Net Income TTM 2.96b / Revenue TTM 21.27b)
Gross Margin = 58.69% ((Revenue TTM 21.27b - Cost of Revenue TTM 8.79b) / Revenue TTM)
Gross Margin QoQ = 60.42% (prev 57.60%)
Tobins Q-Ratio = 1.27 (Enterprise Value 64.90b / Total Assets 50.93b)
Interest Expense / Debt = 1.04% (Interest Expense 126.0m / Debt 12.10b)
Taxrate = 20.05% (225.0m / 1.12b)
NOPAT = 3.24b (EBIT 4.06b * (1 - 20.05%))
Current Ratio = 1.49 (Total Current Assets 12.88b / Total Current Liabilities 8.64b)
Debt / Equity = 0.42 (Debt 12.10b / totalStockholderEquity, last quarter 28.94b)
Debt / EBITDA = 1.64 (Net Debt 9.85b / EBITDA 6.00b)
Debt / FCF = 5.09 (Net Debt 9.85b / FCF TTM 1.93b)
Total Stockholder Equity = 29.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.85% (Net Income 2.96b / Total Assets 50.93b)
RoE = 10.11% (Net Income TTM 2.96b / Total Stockholder Equity 29.23b)
RoCE = 11.40% (EBIT 4.06b / Capital Employed (Equity 29.23b + L.T.Debt 6.37b))
RoIC = 10.26% (NOPAT 3.24b / Invested Capital 31.61b)
WACC = 6.60% (E(55.72b)/V(67.82b) * Re(7.85%) + D(12.10b)/V(67.82b) * Rd(1.04%) * (1-Tc(0.20)))
Discount Rate = 7.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 81.65 | Cagr: 0.11%
[DCF] Terminal Value 82.41% ; FCFF base≈1.97b ; Y1≈1.81b ; Y5≈1.61b
[DCF] Fair Price = 228.5 (EV 39.38b - Net Debt 9.85b = Equity 29.53b / Shares 129.2m; r=6.60% [WACC]; 5y FCF grow -10.45% → 2.90% )
EPS Correlation: -40.63 | EPS CAGR: 3.22% | SUE: 0.81 | # QB: 0
Revenue Correlation: -26.69 | Revenue CAGR: 0.53% | SUE: 1.12 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.98 | Chg7d=+1.976 | Chg30d=+1.976 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=8.16 | Chg7d=-0.083 | Chg30d=-0.145 | Revisions Net=-6 | Growth EPS=-2.3% | Growth Revenue=+0.4%
P/E Trailing = 18.8456
P/E Forward = 14.7275
P/S = 2.6194
P/B = 1.8962
P/EG = 2.697
Revenue TTM = 21.27b EUR
EBIT TTM = 4.06b EUR
EBITDA TTM = 6.00b EUR
Long Term Debt = 6.37b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 1.65b EUR (from shortTermDebt, last quarter)
Debt = 12.10b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 9.85b EUR (from netDebt column, last quarter)
Enterprise Value = 64.90b EUR (55.72b + Debt 12.10b - CCE 2.92b)
Interest Coverage Ratio = 11.30 (Ebit TTM 4.06b / Interest Expense TTM 359.0m)
EV/FCF = 33.56x (Enterprise Value 64.90b / FCF TTM 1.93b)
FCF Yield = 2.98% (FCF TTM 1.93b / Enterprise Value 64.90b)
FCF Margin = 9.09% (FCF TTM 1.93b / Revenue TTM 21.27b)
Net Margin = 13.90% (Net Income TTM 2.96b / Revenue TTM 21.27b)
Gross Margin = 58.69% ((Revenue TTM 21.27b - Cost of Revenue TTM 8.79b) / Revenue TTM)
Gross Margin QoQ = 60.42% (prev 57.60%)
Tobins Q-Ratio = 1.27 (Enterprise Value 64.90b / Total Assets 50.93b)
Interest Expense / Debt = 1.04% (Interest Expense 126.0m / Debt 12.10b)
Taxrate = 20.05% (225.0m / 1.12b)
NOPAT = 3.24b (EBIT 4.06b * (1 - 20.05%))
Current Ratio = 1.49 (Total Current Assets 12.88b / Total Current Liabilities 8.64b)
Debt / Equity = 0.42 (Debt 12.10b / totalStockholderEquity, last quarter 28.94b)
Debt / EBITDA = 1.64 (Net Debt 9.85b / EBITDA 6.00b)
Debt / FCF = 5.09 (Net Debt 9.85b / FCF TTM 1.93b)
Total Stockholder Equity = 29.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.85% (Net Income 2.96b / Total Assets 50.93b)
RoE = 10.11% (Net Income TTM 2.96b / Total Stockholder Equity 29.23b)
RoCE = 11.40% (EBIT 4.06b / Capital Employed (Equity 29.23b + L.T.Debt 6.37b))
RoIC = 10.26% (NOPAT 3.24b / Invested Capital 31.61b)
WACC = 6.60% (E(55.72b)/V(67.82b) * Re(7.85%) + D(12.10b)/V(67.82b) * Rd(1.04%) * (1-Tc(0.20)))
Discount Rate = 7.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 81.65 | Cagr: 0.11%
[DCF] Terminal Value 82.41% ; FCFF base≈1.97b ; Y1≈1.81b ; Y5≈1.61b
[DCF] Fair Price = 228.5 (EV 39.38b - Net Debt 9.85b = Equity 29.53b / Shares 129.2m; r=6.60% [WACC]; 5y FCF grow -10.45% → 2.90% )
EPS Correlation: -40.63 | EPS CAGR: 3.22% | SUE: 0.81 | # QB: 0
Revenue Correlation: -26.69 | Revenue CAGR: 0.53% | SUE: 1.12 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.98 | Chg7d=+1.976 | Chg30d=+1.976 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=8.16 | Chg7d=-0.083 | Chg30d=-0.145 | Revisions Net=-6 | Growth EPS=-2.3% | Growth Revenue=+0.4%